Society for Neuro-Oncology RSS Feed

15th Biennial Canadian Neuro-Oncology Meeting on 9-Feb-12 8:30 AM

Thu, 09 Feb 2012 16:30:00 GMT

15th Biennial Canadian Neuro-Oncology Meeting
Start Date: 9-Feb-12 8:30 AM
End Time: 11-Feb-12 5:30 PM
Location: Rosewood Hotel Georgia, Vancouver, BC
Event Details:

For Online Registration, Hotel Accommodation Details, and Additional Meeting Information, visit: www.cnomeeting.ca

Organizing Committee
Rosemary Cashman, NP
Juliette Hukin, MD
Alan Nichol, MD
Brian Thiessen, MD
Brian Toyota, MD
Stephen Yip, MD, PhD

Rosewood Hotel Georgia

801 West Georgia Street

Vancouver, BC Canada

18th Annual Blood-Brain Barrier Consortium Meeting on 22-Mar-12 8:30 AM

Thu, 22 Mar 2012 15:30:00 GMT

18th Annual Blood-Brain Barrier Consortium Meeting
Start Date: 22-Mar-12 8:30 AM
End Time: 24-Mar-12 12:00 PM
Location: Skamania Lodge, Stevenson, Washington
Event Details:

The 2012 Annual Blood-Brain Barrier Consortium meeting will be held March 22-24, at Skamania Lodge in Stevenson, Washington. The meeting will focus on preclinical and clinical aspects of CNS imaging and the blood-brain barrier. The meeting is partially funded by a National Institutes of Health R13 meeting grant, with support from the National Cancer Institute, National Institute of Neurological Disorders and Stroke, and National Institute of Deafness and Communication Disorders, and is organized in collaboration with the International Brain Barriers Society.

For more information, please visit www.ohsu.edu/bbb.

Skamania Lodge

15th International Symposium on Pediatric Neuro-Oncology on 24-Jun-12 8:30 AM

Sun, 24 Jun 2012 12:30:00 GMT

15th International Symposium on Pediatric Neuro-Oncology
Start Date: 24-Jun-12 8:30 AM
End Time: 27-Jun-12 5:30 PM
Location: Sheraton Centre Toronto Hotel, Toronto, ON M5H 2M9
Event Details:

The International Symposium on Pediatric Neuro-Oncology (ISPNO) is a landmark, biennial event in paediatric medicine which will be held from June 24 - 27, 2012 at the Sheraton Centre Toronto Hotel.

Throughout this four-day symposium, attendees will engage in a multi-disciplinary curriculum and dialogue regarding new surgical treatments, innovative research and advances in paediatric neuro-oncology. This dynamic and interactive forum is designed to significantly expand the knowledge base of attendees and further enhance overall patient care worldwide. The program will feature plenary and poster sessions, as well as an Education Day and a Family Day.

Local Organizing Committee:
Eric Bouffet, Chair
Ute Bartels
David Eisenstat
Cynthia Hawkins
Annie Huang
Laura Janzen
Don Mabbott
Katrin Scheinemann
Uri Tabori

The ispno2012.com website is currently under development. For additional information please contact ISPNO 2012 at info@ispno2012.com.

Sheraton Centre Toronto Hotel

123 Queen Street West

Toronto, ON Canada M5H 2M9

Travel Scholarships Available for SNO Young Investigators to Attend the European Association of Neuro-Oncology Meeting

Chas Haynes - noemail@soc-neuro-onc.org — Tue, 24 Jan 2012 23:00:00 GMT

Travel scholarships available
for SNO young investigators to attend the biennial meeting of the
European Association of Neuro-Oncology
Marseille, France,September 6-9, 2012

Submission deadline: February 27, 2012

This travel scholarship facilitates young clinicians and investigators who are within the first five years of their initial academic appointment to attend the biennial meeting of the European Association of Neuro-Oncology (EANO) to be held in Marseille, France, from September 6-9, 2012. A combined EANO/SNO committee will review submitted abstracts and will award two scholarships.

Scholarship recipients will present their research during an oral platform session of the EANO meeting. Scholarships will cover coach airfare, accommodation and full registration to the EANO meeting.

Submissions for travel scholarships will be accepted only via the on-line abstract site and will be reviewed by a combined EANO/SNO committee. The submission deadline is February 27, 2012.

To access the abstract submission site, click here, or visit:

https://soc-neuro-onc.conference-services.net/authorlogin.asp?conferenceID=3119&language=en-uk

Submission deadline: February 27, 2012

24-Jan-12 5:00 PM

2012 Neuro-Tumor Club Call for Abstracts

Chas Haynes - noemail@soc-neuro-onc.org — Mon, 23 Jan 2012 19:00:00 GMT

18th Neuro-Tumor Club Dinner Meeting at AACR

CALL FOR ABSTRACTS – DUE MARCH 2, 2012

DOWNLOAD ABSTRACT SUBMISSION FORM HERE

Event Date: Monday April 2, 2012; 6:30–10:00pm
Location: Hotel Allegro, 171 W. Randolph, Chicago, IL

Meeting Chair: Jeffery Raizer, MD

RSVP Required, especially if you are NOT presenting!

The 18th Annual Neuro-Tumor Club Dinner Meeting will again take place at the AACR Annual Meeting, this time in Chicago, IL, at the Allegro Hotel. This meeting, for brain tumor researchers attending the AACR Annual Meeting, is organized by the Society for Neuro-Oncology.

As in past years, this event will be an informal and stimulating exchange of late-breaking findings of specific and focused interest to investigators dedicated to brain tumor research. Sponsors will be supporting the event by covering meeting room fees and the cost of drinks and buffet dinner for those who RSVP their attendance at the dinner.

Format

We would like to capitalize on the success of the meeting in past years. The presentations will again be very short (5 slides; 5 minutes) and will focus on themes of critical importance to Neuro-Oncology. A short introduction of the theme will be given by the moderators before the presentations. With only 5 slides to present, the purpose is that “each presenter will make a seminal observation, rebut dogma, disclose a paradox, or offer to crack open a new paradigm”. At the conclusion of each presentation we will have a short discussion. Think collaboration, new perspective, synergy, or a glimpse into your competitor’s lab. If you’ve written a recent review (or are planning to do so) on any of these themes, please offer to give a 3-minute introduction to the topic. Also, if there is a theme you would like to see developed, please feel free to suggest it.

Targeted Themes

1. Geno/Phenotyping and Personalized/Combinatorial Therapy
2. Angiogenesis and Tumor Microenvironment
3. New Gene and Immunotherapy
4. New Tools and Translational Approaches
5. CNS Metastases
6. Biomarkers in Gliomas?
7. Stem Cells
8. Animal Models

Timeline

Deadline, submission of abstracts: Friday, March 2, 2012
Notification sent to selected presenters: Friday, March 16, 2012
Deadline, submission of .ppt files by presenters: Monday, March 26, 2012
Final RSVP for the Dinner Meeting: Monday, March 26, 2012
Neuro Tumor Club Dinner Meeting: Monday, April 2, 6:30-10:00pm

PLEASE NOTE: You are welcome to attend the dinner without submitting an abstract. However, please RSVP with us by March 26, so we know how many people to plan for.

To download an abstract/RSVP form, click here.

Questions? Contact: Linda Greer

23-Jan-12 1:00 PM

New Public Data Resource from the NIH Common Fund’s Epigenomics Program

Fri, 29 Jul 2011 12:00:00 GMT

Researchers in the Reference Epigenome Mapping Consortium, part of the NIH Common Fund’s Roadmap Epigenomics Program (http://commonfund.nih.gov/epigenomics), have begun creating a community resource of genome-wide epigenetic maps in a variety of human primary cell and tissue types. The data currently represent more than 100 samples including adult and fetal cells and tissues, and embryonic and induced pluripotent stem cells. The majority of reference epigenomes being generated contain information about DNA methylation, a core set of histone modifications, chromatin accessibility, and gene expression. A subset of reference epigenomes will also contain an expanded set of at least twenty additional histone modifications. The Consortium’s website (http://roadmapepigenomics.org) provides information about protocols developed by Consortium members, information about data standards, and links to a variety of sites where the epigenomic data can be visualized in a genome browser or downloaded for subsequent analysis

29-Jul-11 7:00 AM

Neuro-Oncology’s New Impact Factor is 5.483

Chas Haynes - noemail@soc-neuro-onc.org — Thu, 30 Jun 2011 15:00:00 GMT

The Society for Neuro-Oncology is pleased to announce that the impact factor for our official journal, Neuro-Oncology, has increased by 10% to reach 5.483, in most recent Journal Citation Reports. This means that Neuro-Oncology has maintained its position as the premier journal in the field. The journal is now ranked 15th out of 185 titles in the clinical neurology category, and 24th out of 184 titles in oncology.

WK Alfred Yung, the journal's editor in chief commented: "I am delighted that Neuro-Oncology has achieved such a high impact factor this year, further cementing its position as the leading journal in the field. I’d like to thank our highly dedicated editorial team, authors and reviewers for their contributions and ongoing support, which enables us to provide the highest quality research to our readers.”

30-Jun-11 10:00 AM

Pediatric Neuro-Oncology Basic and Translational Research Conference Recap

Linda Greer - noemail@soc-neuro-onc.org — Thu, 06 Jan 2011 21:00:00 GMT

2011 Pediatric Neuro-Oncology Basic and Translational Research Conference

May 19-20, 2011, Loews Hotel, New Orleans, Louisiana

The 2011 Pediatric Neuro-Oncology Basic and Translational Research Conference took place at the Loews Hotel in New Orleans, Louisiana May 19-20, 2011. The Conference was made possible thanks to a generous grant from the Pediatric Brain Tumor Foundation (PBTF).

Some 200 clinicians, clinician-scientists, scientists, trainees and students attended this meeting. There were participants from over 13 countries around the world. There were platform and poster presenations in addition to Sunrise Sessions where attendees could “Meet the Experts” in the field. The Sunrise Sessions included topics such as diffuse intrinsic pontine glioma, molecular insights at the crossroads of neurodevelopment in tumorigenesis, translating the genomics of pediatric brain tumors into routine clinical practice, stem cells in pediatric brain tumors, and understanding treatment resistance and recurrence in pediatric brain tumors. A host of superb speakers was selected for these Sunrise sessions, and they were very well attended.

The Scientific Session on Thursday May 19^thwas divided into sessions on the genetics and basic biology of pediatric brain tumors, stem cells in translational therapeutics, pediatric brain tumor models and immunology, and high grade glioma and ependymomas. A major focus on the first day was on the BRAF fusion gene in tumors such as pilocytic astrocytoma. It has only been in the past 2 years that the importance of BRAF has been fully appreciated in pediatric brain tumors, and this Scientificd Session offered some of the latest research and models on this topic.

The session on stem cells covered neural progenitor cells in conditions like neurofibromatosis-1 model systems in mouse and tissue culture, and developmental pathway driven tumors such as the hedgehog pathway in medulloblastoma. The session on brain tumor models focused on medulloblastoma, pilocytic astrocytoma, and tumors found in tuberous sclerosis complex. An outstanding presentation was given on the creation of a novel pilocytic astrocytoma model in mice using activated activated BRAF. The afternoon session on high grade gliomas and ependymomas had research papers on angiogenesis, growth factor activating pathways including IGF-1R and PGF-Ra/b, and genomic alterations especially in ependymoma. A provocative presentation on screening of tumor neural stem cells revealed potential new treatments for ependymoma.

On Friday May 20^th, 2011 the day began with a Scientific Session on medulloblastoma, and several presentations were given which elucidated how far the research has gone with respect to increasing our understanding of the molecular biology of this particular tumor type. Large numbers of medulloblastoma samples have been analyzed in an international consortium that has provided the latest and most up to date genetic cataloging of major changes in medulloblastoma.

The late morning session continued on the theme of medulloblastoma, and research areas such as microRNAs, thrombospondin-1, SGK-1, FSTL5, FBWX7 and H1 were discussed with many of these genes serving as novel targets in this tumor.

From SNO, I should like to thank Fred Lang, President, Chas Haynes, Executive Director, Linda Greer and Jan Esenwein for all their assistance and encouragement. From the PBTF, I should like to thank Dianne Traynor, Executive Director and President, for her support, and continued interest in bringing together the best and brightest individuals working in the field of pediatric neuro-oncology.

The meeting was considered a great success, and a model of its kind for future meetings. Given how rapidly the field is changing, and how enthusiastic attendees were with this Conference, planning is now underway for the next meeting.

Dr. James T. Rutka

MD, PhD, FRCSC, FACS, FAAP, FAAN

RS McLaughlin Professor and Chair

Department of Surgery, University of Toronto

Co-Director, The Arthur and Sonia Labatt

Brain Tumour Research Centre

Professor

6-Jan-11 3:00 PM

2011 Pediatric Neuro-Oncology Basic and Translational Research Conference

Linda Greer - noemail@soc-neuro-onc.org — Thu, 22 Jul 2010 19:00:00 GMT

2011 Pediatric Neuro-Oncology Basic and Translational Research Conference

May 19-20, 2011

Loews Hotel, New Orleans, Louisiana

This meeting was held May 19-20, 2011, in New Orleans, Louisiana, and was a great success. Over 200 pediatric basic and translational scientists from twelve countries were in attendance to share the latest advances in the area of pediatric neuro-oncology. A full meeting recap will be posted shortly.

QUICK LINKS

OVERVIEW

The conference encouraged the sharing of ideas and results, new collaborations, and offered attendees a state-of-the-art update in the field of pediatric brain tumor research. To this end, the Scientific Program Committee created a highly informative and educational program from over 130 accepted abstracts..

The program featured popular and informative plenary sessions and informal poster sessions, as well as “Meet the Expert Sunrise Sessions”, at which attendees caught up with late breaking areas of research and controversies in the field.

This meeting was organized by the Society for Neuro-Oncology with the generous support of the Pediatric Brain Tumor Foundation.

LOCATION

The conference was held at the Loews Hotel, located only steps away from the world-famous French Quarter in New Orleans, Louisiana.

ABSTRACT SUBMISSION

Abstracts were accepted in the following categories:

Atypical Teratoid Rhabdoid Tumor (ATRT)

Basic Biology

Brainstem Tumors

Ependymoma

Immunology/Immunotherapy

Genetics/Epigenetics

Germ Cell Tumors

High Grade Gliomas

Medulloblastoma/PNETs

Pediatric Brain Tumor Models

Stem Cells
Signaling

Translational Therapeutics

SCIENTIFIC PROGRAM COMMITTEE

James Rutka, MD, PhD (Chair)

Mitchel Berger, MD

Darell Bigner, MD, PhD

David Eisenstat, MD

Jonathan Finlay, MD

Richard Gilbertson, MD, PhD
Frederick Lang, MD

Ian Pollack, MD

David Rowitch, MD, PhD

Timothy Van Meter, PhD

EDUCATIONAL OBJECTIVES

After attending the conference, participants should be able to

Perform molecular studies to characterize novel mutations important to pediatric CNS tumors (Knowledge, Competence, and Performance);
Apply innovative tumor analysis techniques to assess molecular response to therapy (Knowledge, Competence, and Performance);
Utilize novel in vitro and in vivo models of pediatric CNS tumors to test targeted therapies (Knowledge, Competence, and Performance);
Incorporate appropriate biomarker studies into clinical trial design for different pediatric CNS tumros to advance understanding of distinctive profiles that may influence therapy (Knowledge, Competence, and Performance).
Target Audience
This program is directed toward pediatric CNS tumor basic and translational scientists, and pediatric neuro-oncologists and medical oncologists.

Educational Methods
Lectures, Interactive Small Group/Breakout Sessions, Poster Sessions

Evaluation
A course evaluation form will provide participants with the opportunity to comment on the value of the program content to their practice decisions, performance improvement activities, or possible impact on patient health status. Participants will also have the opportunity to comment on any perceived commercial bias in the presentations as well as to identify future educational topics.

Accreditation/Credit Designation

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Texas MD Anderson Cancer Center and the Society for Neuro-Oncology. The University of Texas MD Anderson Cancer Center is accredited by the ACCME to provide continuing medical education for physicians.

The University of Texas MD Anderson Cancer Center designates this educational activity for a maximum of 13.25 AMA PRA Category 1 CreditsTM. Physicians should claim only credit commensurate with the extent of their participation in the activity.

CME Certificates and Attendance Verification Certificates
Certificates awarding AMA PRA Category 1 CreditTM or certificates documenting attendance will be distributed to participants when an individual departs the conference. To obtain a CME certificate, physicians must submit a completed evaluation questionnaire and a CME Verification Form.

Upon request, a record of attendance (certificate) will be provided on-site to other health care professionals for requesting credits in accordance with state nursing boards, specialty societies, or other professional associations.

The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest that could potentially affect the information presented. MD Anderson also requires that all faculty disclose any unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products. Specific disclosure will be made to the participants prior to the educational activity.

Agendas are subject to change because we are always striving to improve the quality of your educational experience. MD Anderson may substitute faculty with comparable expertise on rare occasions necessitated by illness, scheduling conflicts, and so forth.

Photographing, audiotaping, and videotaping are prohibited.

22-Jul-10 2:00 PM

2009-2010 Central Brain Tumor Registry of the US Statistical Report

Jan Esenwein - noemail@soc-neuro-onc.org — Sat, 20 Mar 2010 15:00:00 GMT

The Central Brain Tumor Registry of the United States (CBTRUS) announces the publication of its latest statistical report, 2009-2010 CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-2006 (available online at www.cbtrus.org). Data collected by the National Program of Cancer Registries (CDC) and SEER (NCI) from 47 population-based cancer registries were analyzed resulting in an incidence rate of 18.71 cases per 100,000 person-years for all primary brain & central nervous system (CNS) tumors. CBTRUS estimates that 62,930 new cases of primary non-malignant and malignant brain and CNS tumors are expected to be diagnosed in the United States in 2010. Meningioma had the highest incidence and accounted for 33.8% of all primary brain tumors in 2004-2006. Gliomas, including glioblastoma, accounted for 32% of these tumors and 80% of all malignant brain tumors.

This Statistical Report continues the past efforts CBTRUS has made to provide accurate, population–based incidence rates for all primary brain and CNS tumors by histology, age, gender, race and Hispanic origin. As in previous reports, these data have been listed in histologic groupings with improved clinical relevance

Funding for the Central Brain Tumor Registry of the United States in 2008-2009 has been provided by the American Brain Tumor Association (www.abta.org) , the National Brain Tumor Society (www.braintumor.org) , the Pediatric Brain Tumor Foundation (www.pbtfus.org) and from the Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under contract # HHSN26100800766P.

Printed booklets may be requested by contacting cbtrus@aol.com.

20-Mar-10 10:00 AM

SNO Announces First International Outreach Fellowship Recipient

Chas Haynes - noemail@soc-neuro-onc.org — Tue, 24 Nov 2009 19:00:00 GMT

SNO International Outreach Research Fellowship
Supported by the American Brain Tumor Association and EMD Serono

The leadership of the Society for Neuro-Oncology and the SNO International Outreach Committee are pleased to announce that Dr. Yi Lin of China has been selected as the first SNO International Outreach Research Fellow.

This fellowship was made possible through the generous support of the American Brain Tumor Association and EMD Serono.

The purpose of this one-year fellowship is to provide a program for professionals from developing regions to perform clinical, translational or basic research in the area of pediatric or adult neuro-oncology in a clinical and/or laboratory setting in the United States or Canada.

Applications were reviewed based on the novelty and scientific merit of the proposed study and the credentials of the applicant, as well as the potential impact to the advancement of neuro-oncology in the applicant’s home country upon completion of the fellowship. The Tufts Medical Center has agreed to host Dr. Lin for the one-year Fellowship period where she will study under the supervision of Dr. Jay-Jiguang Zhu.

The call for applications for the next fellowship cycle will be announced in June, 2010, and details will be available on this website.

24-Nov-09 1:00 PM

2009 Joint Meeting Recap

Chas Haynes - noemail@soc-neuro-onc.org — Tue, 17 Nov 2009 21:00:00 GMT

This historic meeting, held at the Hilton New Orleans Riverside, New Orleans, Louisiana, on October 22–24, 2009, was the first joint meeting between the Society for Neuro-Oncology and the AANS/CNS Section on Tumors.

The meeting was a huge success, continuing the trend of years past with a record 600 abstracts presented and attendance of over 1,200 people. The meeting was co-chaired by Frederick Lang and Randy Jensen, assisted by a Scientific Committee composed of Abhijit Guha, Michael McDermott, Jeffrey Bruce, Susan Chang, Mark Gilbert, and Michael Vogelbaum, with Terri Armstrong organizing the Quality of Life sessions.The meeting benefitted from the generous sponsorship of many supporters this year. At the Leader level of corporate support were Bristol-Myers Squibb, Genentech, and Schering-Plough; at the Benefactor level were AstraZeneca, the CERN Foundation, and Exelixis; at the Supporter level, EMD Serono; and at the Contributor level, the Tug McGraw Foundation, and Eisai. The SNO Platinum-level supporters were the American Brain Tumor Association, Genentech, EMD Serono, Schering-Plough, the Pediatric Brain Tumor Foundation, and the Sontag Foundation.

In the traditional format of the yearly Society for Neuro-Oncology Meeting, the joint meeting started with an education half-day, with the theme of “Personalized Medicine: Is it the Future or Now?” The goals of this education half-day meeting were to explore the application of individual data to better target, prevent, and treat a particular disease or condition. During the session, the use of personalized clinical, radiographic, genomic, and protein data, as well as personalized epigenetics, was explored. Two speakers each representing the specialties of pathology, surgery, radiation oncology, and medical oncology discussed the technology in their subspecialty and the application of this technology towards personalized medicine. These talks addressed the current status of these applications and the future of personalized medicine. In the beginning session on neuropathology, Kenneth Aldape described the “Predictive and Prognostic Value of Global Profiling Technologies in Neuropathology.” He was followed by Daniel Brat, who spoke on the “Predictive and Prognostic Value of Specific Molecular Biomarkers in Neuropathology.” The surgical session began with Christopher Nimsky, who spoke on “Technology Supporting Personalized Surgical Care.” He was followed by Cameron Brennan, speaking on the topic of “Clinical Decision-making in Surgery Incorporating Molecular Markers.” This session was followed by a session featuring two radiation oncologists: Kristina Tsien, who spoke on the “Technology Supporting Personalized Radiation Oncology,” followed by Minesh Mehta, who discussed the “Role of Molecular Markers in Clinical Decision-making in Radiation Oncology.” The final speakers of the education half-day were Timothy Cloughesy, who spoke on “Molecular Markers for Guiding Decision-making in Personalized Neuro-oncology,” and Mark Gilbert, who discussed “Molecular Markers for Guiding Development of Clinical Trials and Personalized Neuro-oncology.”

Of note, the morning also included the special concurrent session on “Enhancing Quality of Life Throughout the Illness Trajectory.” This was organized by Terri Armstrong from the MD Andersen Cancer Center, Kimberly M. Wallgren from the CERN Foundation and Jennifer Brusstar from the Tug McGraw Foundation. To begin this session, attendees were treated to a moving video-taped welcome message from musician Tim McGraw, who expressed his appreciation to the organizers and participants for the important work they are doing on behalf of brain tumor patients. Walter Bail then discussed “Good News or Bad: Communicating with Your Patient,” and Jeffrey Wefel spoke on the topic of “Chemobrain? Impact of Tumor and Treatment on Neurocognitive Function: What We Know, Where to Go.” This was followed by talks on “Radiation of Brain Metastasis, Toxicity and Interventional Trials” by Paul Brown, “The Other Health Care Professional: Training the Care-giver” by Harriet Patterson, and “Promoting Comfort and Choice at the End of Life” by Sherry Fox.

The Joint Meeting of the Society for Neuro-Oncology and AANS/CNS Section on Tumors began on the afternoon of Thursday, October 22, with a moment of silence and remembrance in honor of Mike Traynor, President and Co-Founder of the Pediatric Brain Tumor Foundation, who had recently passed away. During the Introduction, notice was also made of the passing of Samuel Hassenbush, MD, PhD, for whom a talk later in the meeting was named.

The meeting then started with presentations of the top scoring abstracts. This session was composed of the eight top scoring abstracts of all of the abstracts submitted to the meeting. This preliminary session gave the general membership of the two Societies a chance to hear reports on a variety of great research, in both basic science and clinical research. During this session, the award for excellence in adult clinical research was given to Riccardo Soffietti for his paper, “Adjuvant Whole Brain Radiotherapy versus Observation after Radiosurgery or Surgical Resection of 1–3 Cerebral Metastases: Results of the EORTC 22952-26001 Study.” The award for excellence in adult translational research went to Aaron Tannenbaum for his paper, “Sunitinib Inhibits Glioma Growth by Blocking Progenitor Cell Recruitment.” The award for excellence in adult clinical research was presented to Mei-Yin Polley for the paper, “Six-month Progression-free Survival as an Alternative Primary Efficacy End-Point to Overall Survival in Newly-Diagnosed Glioblastoma Patients Receiving Temozolomide.”

The plenary sessions began with an open abstract session on Tumor Biology. Nine abstracts were presented in this session, and the award for excellence in adult basic research went to Lynette Moore for her paper “ IGFBP2 Is a Candidate Biomarker for INK4-ARF Status and a Therapeutic Target for High-Grade Gliomas.”

In the evening, a poster session and reception allowed attendees to mingle and review the incredible work being done by the members of the two Societies. The evening also included Satellite Symposia sponsored by companies with emerging technologies.

The following day began with sunrise sessions in which the topics of “Neurosurgical Oncological Endoscopy,” “Meningiomas: Current Basic Science and Clinical Treatments,” “Cancer Stem Cells; State of the Hypothesis” and “Metastatic Spine Tumors: Biology and Therapy” were addressed. In each of these sessions, a leader and three or four experts in the field discussed current issues related to the topic of their session.

The morning plenary session was begun with a presentation by the Farber Award winner, Peter Dirks. Dr. Dirks summarized his work on “Brain Tumor Stem Cells” and was well received. This was followed by an open abstract session on Medical Therapies.

After the open abstract session, the keynote speaker, Dr. Ramond Sawaya, addressed the topic of “Neurosurgical Oncology--an Indispensable Partner: Surgeons Can Be Involved in Neuro-oncological Research and Play an Important Role in the Neuro-Oncology Team.” After this interesting keynote address, the remainder of the afternoon was filled with concurrent open abstract sessions on the topics of Surgical Therapies; Experimental and Clinical Therapies; and Epidemiology and Quality of Life; Radiology; Pediatric Basic Science; Immunobiology and Immunotherapy; and Radiation Oncology. During the Epidemiology and Quality of Life session, the award for excellence in quality of life research went to Andrea Pace for her paper on “Palliative Home Care for Brain Tumor Patients: Results and Cost/Utility Analysis of 6 Years of a Pilot Project.” During the Pediatric Basic Science session, the award for excellence in pediatric basic research went to Robert Johnson for his paper on “Radial Glia Are Susceptible to Transformation into Ependymoma by Candidate Human Ependymoma Tumor Suppressor Genes (TSG) and Oncogenes.” The award for excellence in pediatric translational research went to Dominik Sturm for his paper on “Identification of SGK1 as a Novel Prognostic Marker for Disease Outcome in Medulloblastoma.”

That evening, during the second poster session, two awards were given for the best posters. A clinical poster award given to Gurpreet Kapoor from the University of Pennsylvania for his poster on the topic of “Perfusion-Weighted Imaging Identifies MR Surrogates of Malignant Glioma Molecular Subtypes.” A basic science award was given to Haizhong Feung from the University of Pittsburgh for research on the topic of “PDGFR Stimulates Glioma Cell Invasion Through Tyrosine Phosphorylation of a Bipartate Guanine Nucleotide Exchange Factor Dock180.”

As on Friday, Saturday morning began with early morning sunrise sessions in the format of “Meet the Experts.” In these well-attended sessions, the topics of “Epidemiology and Pharmacogenetics”; “Immunotherapy: Current Status of Clinical Trials”; “Medulloblastoma: Current State of Biology and Therapy”; and “-omics and Brain Tumors: Genomics, Proteomics, Metabolomics, Ubiquinomics” were addressed. The morning plenary sessions began with an introduction of the Hassenbusch Lecturer by Frederick Lang. This year’s Hassenbusch Lecturer was Katie Orrico, JD, who heads up the Washington Committee of the AANS/CNS. Ms. Orrico gave a wonderful talk that honored the accomplishments of Sam Hassenbush as well as outlined some of the difficulties facing neurosurgery in the upcoming health reform legislation.

The day concluded with plenary sessions on the topics of “Genomics and Proteomics,” “Stem Cells,” and “Pathological and Prognostic Markers.” The meeting adjourned at noon on Saturday, October 24, with a general consensus that combining the Tumor Section of the AANS/CNS Satellite Meeting and the Society for Neuro-Oncology Annual Meeting provided a wonderful platform for exchange of ideas between the two Societies. Many attendees expressed hope that this will be an ongoing recurring practice in the future.

17-Nov-09 3:00 PM

SNO Partners with Oxford Journals to Publish Neuro-Oncology

Chas Haynes - noemail@soc-neuro-onc.org — Thu, 05 Nov 2009 20:00:00 GMT

Oxford Journals and the Society for Neuro-Oncology (SNO) are pleased to announce a new publishing partnership.

Starting with the 2010 volume year, Oxford Journals will publish Neuro-Oncology, the highest ranked journal in its field with an Impact Factor of 5.0 in 2008.

As a result of this new partnership, SNO members and journal subscribers can look forward to a number of important improvements to the publication, including:

Doubling frequency from bimonthly to monthly publication,

Increased opportunities for publication of cutting-edge and timely clinical, translational and scientific data, and

Four-week lead time from manuscript acceptance to citable publication on-line.

Neuro-Oncology is the official journal of SNO. It has an international readership, and comprises peer-reviewed articles, reviews in all areas of neuro-oncology, symposia on selected topics, published abstracts of annual meetings, society news and announcements from around the world. The SNO leadership looks forward to working with Oxford Journals to ensure that Neuro-Oncology continues to be the leading journal in its field.

For more information on the journal, click here.

5-Nov-09 2:00 PM

2009 Joint Meeting of SNO and AANS/CNS Section on Tumors

noemail@soc-neuro-onc.org — Mon, 03 Aug 2009 18:00:00 GMT

The Society for Neuro-Oncology (SNO) and the AANS/CNS Section on Tumors are joining scientific research efforts to present the latest developments in neuro-oncology and tumor surgery at the 2009 Joint Meeting of the Society for Neuro-Oncology and the AANS/CNS Section on Tumors, October 22-24, 2009 in New Orleans, Louisiana. Register now for the most comprehensive review of cutting-edge laboratory and clinical research in the field of neuro-oncology and tumors! Register for the 2009 Joint Meeting of the Society for Neuro-Oncology and the AANS/CNS Section on Tumors today! The CNS is also offering special registration rates for Joint Meeting attendees who also register for the CNS Annual Meeting. Register through September 23, 2009 and you will receive up to 25% in savings on both meetings. In addition to this exclusive registration rate, the CNS is also offering a number of courses that members of the SNO and the AANS/CNS Section on Tumor attendees will find of value -...

2012 SNO Annual Scientific Meeting & Education Day

Sat, 04 Feb 2012 19:30:52 GMT

The 17th Annual Scientific Meeting and Education of the Society for Neuro-Oncology

November 15-18, 2012

Washington Hilton Hotel

Washington, DC

ABSTRACT SUBMISSION

The abstract submission system will open early February 2012.
The abstract submission deadline will be May 15, 2012.

LOCATION

The 17th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology will be held November 15-18, 2012, at the Washington Hilton Hotel, in Washington, DC. SNO has negotiated a discounted rate of $189.00 per night for the duration of the conference. Rooms at the Hilton may be reserved on-line after March 1, 2012.

EXHIBIT AND SUPPORT OPPORTUNITIES

A full prospectus for exhibit, support and ISS opportunities will be available in early 2012.

TRAVEL SCHOLARSHIPS

Information will be posted mid-2012.

SNO Officers, Staff and Committees

Sat, 04 Feb 2012 18:48:12 GMT

SNO Officers President Kenneth Aldape, MD Vice President Michael Vogelbaum, MD Secretary - Treasurer Nino Chiocca, MD Board of Directors Kenneth Aldape, MD Eric Bouffet, MD Sherry Fox, PhD Mary Lovely, PhD Andrew Parsa, MD David Peereboom, MD Russell Pieper, MD David Reardon, MD Jann Sarkaria, MD Michael Taylor, MD, PhD Past President Frederick Lang, MD Journal Editor in Chief W.K. Alfred Yung, MD SNO Editor C. David James, PhD Society for Neuro-Oncology Foundation Board Mark Gilbert, MD (Foundation President) Mitchel S. Berger, MD Victor A. Levin, MD (Society Founder) Staff J. Charles Haynes, JD Executive Director Tel. 713-526-0269 Fax. 713-526-7787 Jan Esenwein Chief Administrative Officer Tel: 713-745-2264 Fax: 713-794-4999 Linda Greer Membership Manager Tel: 281-554-6589 Fax: 713-583-1345 Committees SNO...

**Event Template -left column - Quick Links

Fri, 20 Jan 2012 16:29:27 GMT

Quick Links

Join SNO
Register
Reserve a room
Travel Scholarships
Young Investigators Lunch
CME Information
Support and Exhibits

Information to be posted soon

SNO History

Tue, 10 Jan 2012 18:27:35 GMT

In the early 1990s, clinical and research activities in neuro-oncology were concentrated in a few major medical centers, but the growing and diverse scientific needs of the existing and emerging scientific community had expanded beyond the scope of the existing organizations. The need for an organized effort to fill this gap and coordinate the activities in neuro-oncology was recognized in late 1994 by Victor Levin, MD, then Chair of the Department of Neuro-Oncology at the University of Texas MD Anderson Cancer Center in Houston, Texas. Dr. Levin, joined by a core group of neuro-oncology professionals from multiple specialties articulated a shared vision of an organization that would promote multidisciplinary interactions and provide balanced representation for all specialties interested in advancing research and treatment of neurological malignancies. On January 31, 1996, SNO was incorporated as a 501(c)(3) non-profit organization in the state of Texas. The first...

International Research Fellowship Host Institutions

Wed, 14 Dec 2011 05:15:38 GMT

The following institutions have agreed to be listed as a potential host for the SNO International Outreach Research Fellow. Applicants for the Fellowship must obtain a letter of support from one of the institutions below verifying the host's commitment to mentoring the applicant and providing the necessary resources for completing the work. Click on the facility for contact information and research/interest information. Barrow Neurological Institute Phoenix, Arizona Cedars-Sinai Medical Center Los Angeles, California City of Hope National Cancer Center Duarte, California Cleveland Clinic Cleveland, Ohio Dana Farber Cancer Institute Boston, Massachusetts Dartmouth-Hitchcock Medical Center Lebanon, New Hampshire Emory University Atlanta, Georgia Harvard Medical School Boston, Massachusetts The Hospital for Sick Children (1) Toronto, Ontario The Hospital for Sick Children (2) Research Institute, Labatts...

Ohio State University

Wed, 14 Dec 2011 04:52:47 GMT

The Ohio State University Medical Center

Department of Radiation Oncology

James Comprehensive Cancer Center

Tzagournis Medical Research Facility #514B

Office: #514B; lab room: #510

420 W 12th Ave

Columbus, OH 43210

USA

Contact:

Deliang Guo, Ph.D.

Deliang.Guo@osumc.edu
614-366-3774

Research Categories:

- Molecular targeted therapy and lipid metabolism in glioblastoma

Research Interests/projects:

- Dr. Guo’s lab is focusing on EGFR/RTKs/PI3K/Akt and Ras/MEK/ERK signaling transduction and cancer metabolism. Recently

he and colleagues uncovered EGFR/PI3K/Akt signaling upregulates SREBP-1 activity to promote de novo fatty acid synthesis

and increase cholesterol uptake in brain tumor patients, and demonstrate SREBP-1 and its regulated key genes ACC, FAS and

LDLR as novel molecular targets in cancer (Guo, et al, PNAS, Science Signaling, and Cancer Discovery 2009). Dr. Guo's work

is committed to unraveling how EGFR/PI3K signaling regulates metabolism network, to unravel the link between glucose

uptake and lipid metabolism, to identify the key molecular targets in this network and develop potent inhibitors to translate

into clinical trial to eradicate cancer cells.

University of Virginia

Mon, 12 Dec 2011 23:19:53 GMT

University of Virginia
Neuro-Oncology Center
Box 800432
Charlottesville, VA 22908-0432
USA

Contact:
David Schiff, M.D.
davidschiff@virginia.edu
434-982-4415

Research Categories:

    -Clinical trials in malignant brain tumors
    -Intracellular signalling in malignant gliomas and medulloblastomas
    -microRNA in glioblastoma
    -Epidemiology of primary brain lymphoma
    -Molecular markers in low-grade gliomas

Research Interests/projects:

-see above

Tufts University

Mon, 12 Dec 2011 23:15:29 GMT

Tufts Medical Center Tufts University School of Medicine 800 Washington St. Neurology, Hematology and Oncology, Box 245 Boston, MA 02111 USA Contact: Lynne P. Taylor, MD LTaylor3@tuftsmedicalcenter.org 617-636-2694 Research Categories: Tufts Medical Center offers both clinical and basic science research opportunities in the area of neuro-onology. -Clinical research include clinical trials design and implementation, study of quality of life of patients receiving chemotherapy and radiation therapy, clinical comparative effectiveness and personalized medicine based on molecular profile, race, age and gender -Basic Science research include stem cell research of GBM tumors, tumor cell signal transduction, increase Temozolomide sensitivity through methylation of MGMT gene in transgenic model, microRNA in gliomas and nano-particle technology application in treatment of gliomas Research Interests/projects: ...

The Hospital for Sick Children (2)

Mon, 12 Dec 2011 23:01:49 GMT

The Hospital for Sick Children's Research Institute
University of Toronto
LaBatts Brain Tumor Center
399 Bathurst St. 4W-446 Western Hospital
Toronto, ON M5T 2S8
Canada

Contact:

Sidney Croul, M.D.: Neuropathology
sidney.croul@uhn.on.ca
416-340-3330

Research Categories:

    -Clinical: intracranial, spinal and peripheral nerve tumors
    - Wet bench-molecular neuro-oncology: primary and secondary brain tumors; peripheral nerve tumors; radiobiology
    -Neuropathology-immunohistochemical and molecular diagnostics

Research Interest/Projects:

     Clinical:
    -Skull base
    -Sellar
    -Radiosurgery
    -Ethics
    -Peripheral nerve

     Wet Bench:
    -Signal transduction
    -Pre-clinical glioma models
    -Angiogenesis
    -Radiobiology of CNS tumors

International Outreach Research Fellowship

Mon, 12 Dec 2011 21:44:04 GMT

The SNO International Outreach Research Fellowship Supported by the American Brain Tumor Association and EMD Serono To download an application, click here. Submission deadline: February 3, 2012 Purpose With generous support from the American Brain Tumor Association (ABTA) and EMD Serono, the Society for Neuro-Oncology has established a $50,000 International Outreach Research Fellowship. The purpose of this one-year fellowship is to provide a program for professionals from outside North America to perform clinical, translational or basic research in the area of pediatric or adult neuro-oncology in a clinical and/or laboratory setting in the United States or Canada. One fellowship award is made each year. Eligibility The fellowship is open to post graduate medical professionals working in the following areas: neurosurgery, neurology, radiation oncology, medical oncology, pathology,...

Lorem ipsum survey

noemail@soc-neuro-onc.org — Fri, 20 Mar 2009 16:43:12 GMT

Objectives:

Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diem nonummynibh euismod tincidunt ut lacreet dolore magna aliguam erat volutpat. Ut wisis enim ad minim veniam, quis nostrud exerci tution ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat. Duis te feugifacilisi.

Duis autem dolor in hendrerit in vulputate velit esse molestie consequat, vel illum dolore eu feugiat nulla facilisis at vero eros et accumsan et iusto odio dignissim qui blandit praesent luptatum zzril delenit au gue duis dolore te feugat nulla facilisi.

Ut wisi enim ad minim veniam, quis nostrud exerci taion ullamcorper suscipit lobortis nisl ut aliquip ex en commodo consequat. Duis te feugifacilisi per suscipit lobortis nisl ut aliquip ex en commodo consequat.Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diem nonummy nibh euismod tincidunt ut lacreet dolore magna aliguam erat volutpat.

Mon, 06 Feb 2012 10:34:42 GMT

File uploaded by SNO

Lorem ipsum

2009-03-20T16:43:11Z

Instructor: Instructor

Lorem ipsum